Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen, Seegene Ink MDx Development Agreement

NEW YORK (GenomeWeb) – Seegene will develop a menu of multiplex assay panels for Qiagen's QIAsymphony RGQ molecular diagnostics platform under a partnership announced by the companies today.

The first project under the partnership is to develop comprehensive panels to profile infectious diseases. Seegene's proprietary technologies for multiplexed real-time PCR analysis enable simultaneous amplification of up to 20 target genes per tube.

Qiagen will validate the tests to run on the QIAsymphony RGQ, its modular, automated, real-time PCR-based molecular MDx system, and will market the assays worldwide as Qiagen-branded products, beginning in Europe and Asia.

"Seegene's technologies can test for multiple targets with high sensitivity [and] reproducibility, and the panels offer significant medical value," Thierry Bernard, senior vice president and head of molecular diagnostics at Qiagen, said in a statement.

"Collaborating with Qiagen to commercialize comprehensive multiplexed panels based on our innovative PCR chemistry technologies will expand Seegene's global reach," Seegene Founder and CEO Jong-Yoon Chun noted in a statement. "Because our breakthrough MuDT technology enables detection and quantification of multiple target genes in a single channel without melt curve analysis, this is a true next-generation qPCR technology."

This is the second major global original design manufacturing deal that Seegene has entered into. In November, Seegene and Beckman Coulter inked a deal under which Seegene will manufacture reagents for Beckman Coulter's new Veris MDx sample-to-answer molecular diagnostics system.